


Replace the paragraph beginning at page 13, line 20 and ending at page 14, line 4 with the following amended paragraph rewritten in clean form:

a2 Fig 13. is an illustration showing a sequence alignment of the human kappa opioid receptor (ork), the rat kappa opioid receptor (orkr), the human mu opioid receptor (orm), the rat mu opioid receptor (ormr), the human delta opioid receptor (ord), the rat type 1A angiotensin II receptor (AT1A), and the human bradykinin receptor (B2)(SEQ ID NOs: 76-82). Also shown is the N residue, which is located 14 amino acids to the amino-terminus of the "DRY" motif (-14).

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 April 2002

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

\\Clark-w2k1\documents\00398\00398.510002 Preliminary Amendment.wpd

VERSION WITH MARKINGS TO SHOW CHANGES

Replace the paragraph beginning at page 12, line 5 and ending at line 7 with the following amended paragraph:

Fig 1. is a table of constitutively active Class A G protein-coupled receptors (SEQ ID NOs: 2-75[70]). The mutations that impart constitutive activity to the receptors are indicated.

Replace the paragraph beginning at page 13, line 20 and ending at page 14, line 4 with the following amended paragraph:

Fig 13. is an illustration showing a sequence alignment of the human kappa opioid receptor (ork), the rat kappa opioid receptor (orkr), the human mu opioid receptor (orm), the rat mu opioid receptor (ormr), the human delta opioid receptor (ord), the rat type 1A angiotensin II receptor (AT1A), and the human bradykinin receptor (B2)(SEQ ID NOs: [71-77] 76-82). Also shown is the N residue, which is located 14 amino acids to the amino-terminus of the "DRY" motif (-14).